// App-Quantinova.ai

10527 : Prognostic factors in stage 4 neuroblastoma treated with busulphan-melphalan: Report from the European HR-NBL1/Siopen trial.

Researchers

Presenter

  • Ruth Ladenstein

Principal Investigators

  • Martin Elliott

  • Roberto Luksch

  • Victoria Castel

  • Isaac Yaniv

  • Vassilios Papadakis

  • Genevieve Laureys

  • Josef Malis

  • Walentyna Balwierz

  • Ellen Ruud

  • Per Kogner

  • Henrik Schroeder

  • Ana Forjaz De Lacerda

  • Maja Beck Popovic

  • Pavel Bician

  • Miklos Garami

  • Toby Trahair

  • Andrew DJ Pearson

  • Dominique Valteau Couanet

Medical Centers

  • St. Anna Children's Hospital and Research Institute for the SIOP Europe Neuroblastoma Group, Paediatric Haematology/Oncology, Vienna, Austria

  • St. Anna Children's Cancer Research Institute, Vienna, Austria

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Istituto Nazionale Tumori, Milano, Italy

  • Pediatric Hematology and Oncology, Pediatric Oncology Unit Hospital La Fe Valencia, Valencia, Spain

  • Pediatric Hematology Oncology, Schneider Children's Medical Center of Israel, Petah-Tikva, Israel

  • Agia Sofia Children's Hospital Athens, Athens, Greece

  • University Hospital Gent, Gent, Belgium

  • University Hospital Motol, Prague, Czech Republic

  • Jagiellonian University Medical College, Cracow, Poland

  • Rikshospitalet, Oslo, Norway

  • Karolinska University Hospital, Stockholm, Sweden

  • University Hospital of Aarhus, Skejby, Aarhus, Denmark

  • Portuguese Institute of Oncology, Lisbon, Portugal

  • Pediatric Hematology-Oncology Unit, University Hospital, Lausanne, Switzerland

  • University Children's Hospital, Banska Bystrica, Slovakia

  • Semmelweis University, Budapest, Hungary

  • Sydney Children's Hospital, Randwick, Australia

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Institut Gustave-Roussy, Villejuif, France

Locations

  • Czech Republic

  • Italy

  • Austria

  • Greece

  • Norway

  • Poland

  • Spain

  • United Kingdom

  • Sweden

  • Switzerland

  • Australia

  • Portugal

  • Israel

  • France

  • Slovakia

  • Denmark

  • Belgium

  • Hungary

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Neuroblastoma

Biomarkers

  • MYCN proto-oncogene, bHLH transcription factor

  • Hormone receptor

Drug/Treatment

  • Melphalan

  • Busulfex

  • Tigason

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01704716

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved